信达生物制药（01801）于2026年3月5日披露截至2026年2月28日的股份变动月报表。报告显示，公司法定注册股本维持在5,000,000,000股（面值USD 0.00001），注册股本总额为USD 50,000。已发行股份数量为1,735,186,039股，与上月底相同，未见新增发行或回购、注销及库藏股变动。
期权与激励计划方面，首发前股份奖励计划、首发后员工持股计划及2024年股份计划在报告期内均无行使或新增发行。部分期权被注销24,750股，但并未导致公司已发行股份总数发生变化。公司表示，将继续遵守香港联合交易所有限公司《上市规则》及相关法律法规。此次月报由公司联席公司秘书签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.